Literature DB >> 798488

Role of prostaglandins in the pathogenesis of Bartter's syndrome.

M P Fichman, N Telfer, P Zia, P Speckart, M Golub, R Rude.   

Abstract

Increased renal prostaglandins activated by beta-catecholamines could produce renal tubular sodium wasting and angiotensin pressor resistance observed in Bartter's syndrome. We therefore measured plasma renin activity (PRA), aldosterone and prostaglandin A (PGA) by radioimmunoassay, and body composition by isotope dilution prior to and following beta-adrenergic blockade with propranolol (200 mg/day for 4 days) and prostaglandin synthesis inhibition by indomethacin (200 mg/day for 4 days) in a patient with Bartter's syndrome on a 250 meq sodium diet. After the administration of propranolol, body weight increased 3 kg, daily urine sodium decreased within 24 hours from 230 to 64 meq, and urine potassium from 102 to 45 meq, but PRA and the aldosterone level remained elevated. With the administration of indomethacin, body weight increased 5 kg, daily urinary sodium decreased within 24 hours to 11meq and urine potassium to 16 meq, PRA (normal less than 3 ng/100 ml/hour) decreased from 55 to 4.3 ng/ml/hour, plasma aldosterone (normal less than 8 ng/100 ml) from 74.1 to 3.6 ng/100 ml, and whole blood PGA (normal 546 +/- 307 pg/ml) decreased from 1,390 and 945 to 86 pg/ml. After the administration of propranolol or indomethacin, exchangeable sodium, total body water, extracellular volume and plasma volume all increased from less than to greater than predicted, and pressor resistance to angiotensin was normalized. These results suggest that Bartter's syndrome results from beta adrenergic and prostaglandin-mediated proximal tubular rejection of sodium leading to increased distal sodium-potassium exchange.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 798488     DOI: 10.1016/0002-9343(76)90892-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  23 in total

1.  [Secondary gout and pseudo-Bartter syndrome in females with laxative abuse].

Authors:  O Adam; F D Goebel
Journal:  Klin Wochenschr       Date:  1987-09-01

2.  Treatment of Bartter's syndrome in early childhood with prostaglandin synthetase inhibitors.

Authors:  J M Littlewood; M R Lee; S R Meadow
Journal:  Arch Dis Child       Date:  1978-01       Impact factor: 3.791

Review 3.  [Bartter's syndrome].

Authors:  R Düsing; F C Bartter; J R Gill; F Krück; H J Kramer
Journal:  Klin Wochenschr       Date:  1983-04-01

4.  Effects of drugs on sodium metabolism.

Authors:  M R Lee
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

Review 5.  The involvement of arachidonic acid metabolism in the control of renin release.

Authors:  C Patrono; F Pugliese
Journal:  J Endocrinol Invest       Date:  1980 Apr-Jun       Impact factor: 4.256

6.  Prostaglandin synthetase inhibitor in an infant with congenital chloride diarrhoea.

Authors:  A M Minford; D G Barr
Journal:  Arch Dis Child       Date:  1980-01       Impact factor: 3.791

7.  Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin.

Authors:  J Watkins; E C Abbott; C N Hensby; J Webster; C T Dollery
Journal:  Br Med J       Date:  1980-09-13

8.  The kallikrein-kinin system in Bartter's syndrome and its response to prostaglandin synthetase inhibition.

Authors:  J M Vinci; J R Gill; R E Bowden; J J Pisano; J L Izzo; N Radfar; A A Taylor; R M Zusman; F C Bartter; H R Keiser
Journal:  J Clin Invest       Date:  1978-06       Impact factor: 14.808

9.  The effect of altered sodium balance upon renal vascular reactivity to angiotensin II and norepinephrine in the dog. Mechanism of variation in angiotensin responses.

Authors:  J A Oliver; P J Cannon
Journal:  J Clin Invest       Date:  1978-03       Impact factor: 14.808

Review 10.  The Drosophila melanogaster model for Cornelia de Lange syndrome: Implications for etiology and therapeutics.

Authors:  Dale Dorsett
Journal:  Am J Med Genet C Semin Med Genet       Date:  2016-04-20       Impact factor: 3.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.